Cyber Crime
Dear Colleagues I would like to make you aware about an increase in the number of fraudulent or ‘phishing’ emails…
NICE has republished its guidance TA878 – Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19. The recommendation to extend access to treatment for a broader eligible population (people with diabetes, obesity or heart failure, or aged 70 years or over) has been withdrawn. In line with the original recommendation, Nirmatrelvir plus ritonavir (Paxlovid) is only recommended for patients at highest risk of serious illness as defined in Section 5 of TA878.
These changes mean that some additional groups that were eligible for treatment during the period of the funding variation are no longer subject to a NICE recommendation. These include:
Dear Colleagues I would like to make you aware about an increase in the number of fraudulent or ‘phishing’ emails…
Following a meeting we had with Jane Schofield, Informatics Consultant for the Digital Transformation team at NHS South, Central and…
In response to member queries regarding the future management of physician associates (PAs) within their practices, please note the additional…